- Pfizer (NYSE:PFE) said that it has begun a rolling submission of its COVID-19 antiviral Paxlovid (PF-07321332 and ritonavir) with Health Canada.
- The submission includes an analysis of data from a phase 2/3 trial.
- Paxlovid is intended for treatment of mild to moderate COVID-19 in adults at increased risk of hospitalizations or death.
- Pfizer sought Emergency Use Authorization for Paxlovid with the FDA last month.